Viewing Study NCT02676869


Ignite Creation Date: 2025-12-24 @ 10:55 PM
Ignite Modification Date: 2025-12-25 @ 8:23 PM
Study NCT ID: NCT02676869
Status: COMPLETED
Last Update Posted: 2019-12-18
First Post: 2016-02-02
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Sponsor: Immutep Australia Pty. Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Annotation Module